SG11201902529WA - Naphthyridinone derivatives and their use in the treatment of arrhythmia - Google Patents
Naphthyridinone derivatives and their use in the treatment of arrhythmiaInfo
- Publication number
- SG11201902529WA SG11201902529WA SG11201902529WA SG11201902529WA SG11201902529WA SG 11201902529W A SG11201902529W A SG 11201902529WA SG 11201902529W A SG11201902529W A SG 11201902529WA SG 11201902529W A SG11201902529W A SG 11201902529WA SG 11201902529W A SG11201902529W A SG 11201902529WA
- Authority
- SG
- Singapore
- Prior art keywords
- novartis
- cambridge
- international
- institutes
- avenue
- Prior art date
Links
- 206010003119 arrhythmia Diseases 0.000 title abstract 2
- 230000006793 arrhythmia Effects 0.000 title abstract 2
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical class C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000124815 Barbus barbus Species 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 3E1 0 0111E1111001 HE ME 110 11110 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/073788 Al 26 April 2018 (26.04.2018) WIP0 I PCT (51) International Patent Classification: gin; Novartis Institutes for BioMedical Research, Inc., CO7D 471/04 (2006.01) A61P 9/06 (2006.01) 250 Massachusetts Avenue, Cambridge, MA 02139 (US). A61K 31/4375 (2006.01) LIAO, Lv; Shanghai Novartis Trading Ltd., 4218 Jinke (21) International Application Number: Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203 (CN). MA, Fupeng; Novartis Institutes for BioMedical Re- PCT/IB2017/056515 search, Inc., 250 Massachusetts Avenue, Cambridge, MA (22) International Filing Date: 02139 (US). MO, Ruowei; Novartis Institutes for BioMed- 19 October 2017 (19.10.2017) ical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). PARKER, David Thomas; 25 Crestwood (25) Filing Language: English Road, Windham, NH 03087 (US). PENG, Yunshan; No- (26) Publication Language: English vartis Institutes for Biomedical Research, Inc., 250 Mass- achusetts Avenue, Cambridge, MA 02139 (US). PEUK- (30) Priority Data: ERT, Stefan; Novartis Institutes for Biomedical Research, PCT/CN2016/102928 Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 21 October 2016 (21.10.2016) CN (US). YAMADA, Ken; Novartis Institutes for Biomed- 62/410,930 21 October 2016 (21.10.2016) US ical Research, Inc., 250 Massachusetts Avenue, Cambridge, 62/413,292 26 October 2016 (26.10.2016) US MA 02139 (US). YASOSHIMA, Kayo; Novartis Institutes (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, for Biomedical Research, Inc., 250 Massachusetts Avenue, 4056 Basel (CH). Cambridge, MA 02139 (US). (72) Inventors: BARBE, Guillaume; 583 Pleasant Street, Mil- (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel ton, MA 02186 (US). BEBERNITZ, Gregory Raymond; (CH). _ 799 Bartlett Carry Road, Tupper Lake, NY 12986 (US). (81) Designated States (unless otherwise indicated, for every = GENG, Sicong; Jinke Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai Shanghai Novartis Trading Ltd., 4218 kind AO, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, _ 201203 (CN). CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, GULGEZE EFTHYMIOU, Hatice Bel- CA, (54) Title: NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA (57) : The present invention provides a compound of formu- = = ElgUre 1. PCIRP0.0 example 1 11Yd.R 1 0 X.R. e la (I) or a pharmaceutically acceptable salt thereof; (I) Wherein R 1 , R 3 -R 6 , X 2 and X 3 are as defined herein, a method for manufacturing = the compounds of the invention, and its therapeutic uses. The present i invention further provides a combination of pharmacologically active = = agents and a pharmaceutical composition. I = _ = = h = = _ _ = — Il GC CI 11 0 R s GC R° IN en N R' IN I 1 1 © ,-.... x ,...,„. 11 Fe 0 (I) © N O [Continued on next page] WO 2018/073788 Al MIDEDIMOMOIDEIREEMOOMEIIIIIIIIMOMEEN DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662410930P | 2016-10-21 | 2016-10-21 | |
CN2016102928 | 2016-10-21 | ||
US201662413292P | 2016-10-26 | 2016-10-26 | |
PCT/IB2017/056515 WO2018073788A1 (en) | 2016-10-21 | 2017-10-19 | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201902529WA true SG11201902529WA (en) | 2019-05-30 |
Family
ID=60409317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201902529WA SG11201902529WA (en) | 2016-10-21 | 2017-10-19 | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
Country Status (33)
Country | Link |
---|---|
US (3) | US10266531B2 (en) |
EP (2) | EP3529251B1 (en) |
JP (1) | JP7030802B2 (en) |
KR (1) | KR102540872B1 (en) |
CN (1) | CN109843887B (en) |
AU (2) | AU2017344489C1 (en) |
BR (1) | BR112019007863A2 (en) |
CA (1) | CA3038624A1 (en) |
CL (1) | CL2019001023A1 (en) |
CO (1) | CO2019003894A2 (en) |
CR (1) | CR20190201A (en) |
CU (1) | CU24599B1 (en) |
DO (1) | DOP2019000100A (en) |
EC (1) | ECSP19026973A (en) |
ES (1) | ES2934234T3 (en) |
FI (1) | FI3529251T3 (en) |
HR (1) | HRP20221516T1 (en) |
HU (1) | HUE060882T2 (en) |
IL (1) | IL266128B (en) |
JO (1) | JOP20190086A1 (en) |
LT (1) | LT3529251T (en) |
MX (1) | MX2019004484A (en) |
PE (1) | PE20190735A1 (en) |
PH (1) | PH12019500849A1 (en) |
PL (1) | PL3529251T3 (en) |
PT (1) | PT3529251T (en) |
RS (1) | RS63841B1 (en) |
SA (1) | SA519401614B1 (en) |
SG (1) | SG11201902529WA (en) |
SI (1) | SI3529251T1 (en) |
TW (1) | TWI759343B (en) |
UY (1) | UY37445A (en) |
WO (1) | WO2018073788A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190086A1 (en) | 2016-10-21 | 2019-04-18 | Novartis Ag | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
SG11202012973RA (en) * | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
WO2022074567A1 (en) | 2020-10-06 | 2022-04-14 | Novartis Ag | Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia |
AR127698A1 (en) * | 2021-11-23 | 2024-02-21 | Novartis Ag | NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1022214A (en) | 1963-01-31 | 1966-03-09 | Sterling Drug Inc | Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation |
IL51092A0 (en) | 1976-12-10 | 1977-02-28 | Abic Ltd | Naphthyridine derivatives and their preparation |
JPS57176958A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation |
JPS57176956A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
JPS57176959A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation |
JPS57176957A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US4559332A (en) | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
US4698341A (en) | 1983-07-30 | 1987-10-06 | Godecke Aktiengesellschaft | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis |
US4767762A (en) * | 1985-12-23 | 1988-08-30 | Abbott Laboratories | Tricyclic quinoline and naphthyride antibacterials |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
ATE164852T1 (en) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | GLP-1 ANALOGUE USABLE IN DIABETES TREATMENT |
AU1625192A (en) | 1991-05-31 | 1992-12-03 | Zeneca Limited | Heterocyclic derivatives |
EP0618803A4 (en) | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments. |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5910498A (en) | 1994-10-20 | 1999-06-08 | Wakunaga Seiyaku Kabushiki Kaisha | Pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents comprising the same as active ingredient |
WO1997040036A1 (en) | 1996-04-19 | 1997-10-30 | Wakunaga Pharmaceutical Co., Ltd. | Novel pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents containing the same as the active ingredient |
DE19616486C5 (en) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Method for lowering the blood glucose level in mammals |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
KR100516379B1 (en) | 1996-11-28 | 2005-09-26 | 와쿠나가 세이야쿠 가부시키 가이샤 | Novel pyrodonecarboxylic acid derivative or salt thereof and medicine comprising the same as active ingredient |
WO1999064400A1 (en) | 1998-06-12 | 1999-12-16 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
CA2339484A1 (en) | 1998-08-03 | 2000-02-17 | Robert A. O'brien | Pyridinones for the treatment of sexual dysfunction |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
GT199900147A (en) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED. | |
CO5150173A1 (en) | 1998-12-10 | 2002-04-29 | Novartis Ag | COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION |
US6677341B2 (en) | 1999-09-23 | 2004-01-13 | Pharmacia Corporation | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
SK14612002A3 (en) | 2000-04-12 | 2003-05-02 | Novartis Ag | Novel medical use of aldosterone synthase inhibitors alone or in combination with AT1-receptor antagonists |
JP2003040866A (en) | 2001-07-31 | 2003-02-13 | Nippon Kayaku Co Ltd | N-substituted indole derivative, method for producing the same, and pest-controlling agent containing the same as active ingredient |
PL369567A1 (en) * | 2001-09-26 | 2005-05-02 | Bayer Pharmaceuticals Corporation | 1,6-naphthyridine derivatives as antidiabetics |
WO2003063781A2 (en) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
EP1513840B1 (en) | 2002-05-31 | 2006-10-04 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
PT1537114E (en) | 2002-08-07 | 2006-12-29 | Novartis Ag | Organic compounds as agents for the treatment of aldosterone mediated conditions |
PT1565463E (en) | 2002-11-18 | 2008-09-10 | Novartis Ag | Imidazo[1,5a] pyridine derivatives and methods for treating aldosterone mediated diseases |
EP1670795A1 (en) | 2003-09-18 | 2006-06-21 | ALTANA Pharma AG | Pharmacologically active imidazo 4,5-c pyridines |
US7906521B2 (en) | 2003-09-23 | 2011-03-15 | Merck Sharp & Dohme Corp. | Quinazoline potassium channel inhibitors |
PT1732933E (en) | 2004-03-26 | 2008-10-20 | Lilly Co Eli | Compounds for treating dyslipidemia |
UA90269C2 (en) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Tetrahydroquinoline derivatives and a process for preparing the same |
DE102004018198A1 (en) | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | sulfonamides |
EP1748986B1 (en) | 2004-05-28 | 2010-12-01 | Novartis AG | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
US7612088B2 (en) | 2004-05-28 | 2009-11-03 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
EP1749005A1 (en) | 2004-05-28 | 2007-02-07 | Speedel Experimenta AG | Tetrahydro-imidazo ¬1,5-a| pyridin derivatives as aldosterone synthase inhibitors |
ES2656017T3 (en) | 2004-06-24 | 2018-02-22 | Vertex Pharmaceuticals Incorporated | Conveyor modulators of the ATP binding cassette |
AR049711A1 (en) | 2004-07-09 | 2006-08-30 | Speedel Experimenta Ag | HETEROCICLIC COMPOUNDS CONDENSED AS INHIBITORS OF ALDOSTERONE SINTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF DISEASES RELATED TO HYPERALDOSTERISM AND EXCESSIVE CORTISO RELEASE |
DE102004054215A1 (en) | 2004-11-10 | 2006-05-11 | Merck Patent Gmbh | Pyridopyrimidinonderivate |
TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
AU2006261841B8 (en) | 2005-06-27 | 2012-12-06 | Exelixis Patent Company Llc | Pyrazole based LXR modulators |
GT200600381A (en) | 2005-08-25 | 2007-03-28 | ORGANIC COMPOUNDS | |
EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
EP1956910B1 (en) | 2005-11-23 | 2014-09-17 | The Board of Regents of The University of Texas System | Oncogenic ras-specific cytotoxic compound and methods of use thereof |
AR056888A1 (en) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | HIDEROCICLIL IMIDAZOL DERIVATIVES |
WO2007116908A1 (en) | 2006-04-04 | 2007-10-18 | Taiyo Nippon Sanso Corporation | Method for separation of methane, methane separator, and methane utilization system |
TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
JP2010501573A (en) | 2006-08-25 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | Condensed imidazole derivatives for the treatment of diseases mediated by aldosterone synthase and / or 11-β-hydroxylase and / or aromatase |
RU2009127642A (en) | 2006-12-18 | 2011-01-27 | Новартис АГ (CH) | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR APPLICATION AS ALDOSTEROSYNTHASE INHIBITORS |
US8143278B2 (en) | 2006-12-18 | 2012-03-27 | Novartis Ag | Organic compounds |
AU2007334416A1 (en) | 2006-12-18 | 2008-06-26 | Novartis Ag | Imidazoles as aldosterone synthase inhibitors |
DE602008003015D1 (en) | 2007-03-29 | 2010-11-25 | Novartis Ag | HETEROCYCLIC SPIRO COMPOUNDS |
JP5355582B2 (en) | 2008-02-22 | 2013-11-27 | 大塚製薬株式会社 | Benzodiazepine compounds and pharmaceutical compositions |
WO2010012745A2 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | Benzimidazoles |
WO2011018611A1 (en) | 2009-08-10 | 2011-02-17 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
GB0917571D0 (en) | 2009-10-07 | 2009-11-25 | Karobio Ab | Novel estrogen receptor ligands |
DK2610255T3 (en) | 2010-08-25 | 2016-05-30 | Neopharm Co Ltd | 1H-benzo [d] imidazol-5-yl compounds and a composition for the treatment of inflammatory diseases |
EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
WO2013007676A1 (en) | 2011-07-12 | 2013-01-17 | F. Hoffmann-La Roche Ag | Aminomethyl quinolone compounds |
AU2013203252B2 (en) | 2012-01-27 | 2015-08-20 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
WO2013152063A1 (en) | 2012-04-05 | 2013-10-10 | Boehringer Ingelheim International Gmbh | Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase |
US9067894B1 (en) | 2013-03-07 | 2015-06-30 | Vanderbilt University | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest |
WO2014152317A2 (en) | 2013-03-15 | 2014-09-25 | Melinta Therapeutics, Inc. | Methods of treating gonorrhea infections using quinolone antibiotics |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
AR096022A1 (en) | 2013-04-11 | 2015-12-02 | Basf Se | SUBSTITUTED PYRIMIDINUM COMPOUNDS, USEFUL TO COMBAT ANIMAL PESTS |
WO2015019347A1 (en) | 2013-08-08 | 2015-02-12 | Yeda Research And Development Company Ltd. | Girk as a therapeutic target of immune disorders and a marker of b cell subtypes |
EP3088399A4 (en) | 2013-12-26 | 2017-10-25 | Kinki University | Alkoxycarbonyl hemiacetal-type ester prodrug of pyridone carboxylic acid antibacterial drug |
CA2958645A1 (en) | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
KR20180016485A (en) * | 2015-06-09 | 2018-02-14 | 바이엘 파마 악티엔게젤샤프트 | Positive allosteric modulator of muscarinic M2 receptor |
JOP20190086A1 (en) | 2016-10-21 | 2019-04-18 | Novartis Ag | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
-
2017
- 2017-06-16 JO JOP/2019/0086A patent/JOP20190086A1/en unknown
- 2017-10-18 UY UY0001037445A patent/UY37445A/en not_active Application Discontinuation
- 2017-10-19 SG SG11201902529WA patent/SG11201902529WA/en unknown
- 2017-10-19 PT PT178011052T patent/PT3529251T/en unknown
- 2017-10-19 PE PE2019000829A patent/PE20190735A1/en unknown
- 2017-10-19 TW TW106135836A patent/TWI759343B/en active
- 2017-10-19 SI SI201731279T patent/SI3529251T1/en unknown
- 2017-10-19 EP EP17801105.2A patent/EP3529251B1/en active Active
- 2017-10-19 AU AU2017344489A patent/AU2017344489C1/en active Active
- 2017-10-19 CU CU2019000042A patent/CU24599B1/en unknown
- 2017-10-19 US US15/788,248 patent/US10266531B2/en active Active
- 2017-10-19 BR BR112019007863A patent/BR112019007863A2/en active Search and Examination
- 2017-10-19 ES ES17801105T patent/ES2934234T3/en active Active
- 2017-10-19 JP JP2019520981A patent/JP7030802B2/en active Active
- 2017-10-19 MX MX2019004484A patent/MX2019004484A/en unknown
- 2017-10-19 CA CA3038624A patent/CA3038624A1/en active Pending
- 2017-10-19 HR HRP20221516TT patent/HRP20221516T1/en unknown
- 2017-10-19 CN CN201780063857.XA patent/CN109843887B/en active Active
- 2017-10-19 FI FIEP17801105.2T patent/FI3529251T3/en active
- 2017-10-19 LT LTEPPCT/IB2017/056515T patent/LT3529251T/en unknown
- 2017-10-19 PL PL17801105.2T patent/PL3529251T3/en unknown
- 2017-10-19 WO PCT/IB2017/056515 patent/WO2018073788A1/en unknown
- 2017-10-19 EP EP22195204.7A patent/EP4141006A1/en not_active Withdrawn
- 2017-10-19 HU HUE17801105A patent/HUE060882T2/en unknown
- 2017-10-19 KR KR1020197014044A patent/KR102540872B1/en active IP Right Grant
- 2017-10-19 CR CR20190201A patent/CR20190201A/en unknown
- 2017-10-19 RS RS20221152A patent/RS63841B1/en unknown
-
2019
- 2019-03-01 US US16/290,313 patent/US10844055B2/en active Active
- 2019-04-15 CL CL2019001023A patent/CL2019001023A1/en unknown
- 2019-04-15 EC ECSENADI201926973A patent/ECSP19026973A/en unknown
- 2019-04-16 DO DO2019000100A patent/DOP2019000100A/en unknown
- 2019-04-16 CO CONC2019/0003894A patent/CO2019003894A2/en unknown
- 2019-04-17 PH PH12019500849A patent/PH12019500849A1/en unknown
- 2019-04-18 SA SA519401614A patent/SA519401614B1/en unknown
- 2019-04-18 IL IL266128A patent/IL266128B/en active IP Right Grant
-
2020
- 2020-06-29 AU AU2020204341A patent/AU2020204341B2/en active Active
- 2020-10-15 US US17/071,311 patent/US11530213B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201908977SA (en) | Niraparib formulations | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201902529WA (en) | Naphthyridinone derivatives and their use in the treatment of arrhythmia | |
SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201908660RA (en) | N-substituted indole derivatives | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
SG11201811712QA (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
SG11201809561WA (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases |